Vorapaxar, a novel oral antiplatelet drug.

Simple item page
dc.contributor.authorTekulapally, Kranti
dc.date.accessioned2015-11-04T06:35:32Z
dc.date.available2015-11-04T06:35:32Z
dc.date.issued2015-01
dc.description.abstractVorapaxor is first in the class of protease activated receptor 1 (PAR 1) antagonists. It acts by inhibiting the binding of thrombin to PAR 1 and thereby prevents platelet aggregation. USFDA approved it in May 2014 as the results of clinical trials showed that the benefit: risk ratio was high. It is to be used in a dose of 2.5 mg once daily as triple antiplatelet therapy with aspirin and clopidogrel for reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction or peripheral arterial disease. Increase in the incidence of intracranial hemorrhage is the major side-effect seen.en_US
dc.identifier.citationTekulapally Kranti. Vorapaxar, a novel oral antiplatelet drug. International Journal of Basic & Clinical Pharmacology. 2015 Jan-Feb; 4(1): 188-190.en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/165025
dc.language.isoenen_US
dc.source.urihttps://www.ijbcp.com/?mno=173368en_US
dc.subjectVorapaxaren_US
dc.subjectProtease activated receptor 1 antagonsiten_US
dc.subjectThrombin receptor antagonisten_US
dc.titleVorapaxar, a novel oral antiplatelet drug.en_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijbcp2015v4n1p188.pdf
Size:
228.61 KB
Format:
Adobe Portable Document Format
Description:
New drug update
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
International Journal of Basic & Clinical Pharmacology